Non-Hodgkin's Lymphoma (NHL) Clinical Trial
Official title:
A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90-Yttrium- Zevalin and the Redox- Modulating Agent, Motexafin Gadolinium (MGd)
Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate
cancer cells and either kill them or deliver radioactive cancer-killing substances to them
without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium
Y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug.
This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when
administered with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they
work in treating patients with stage II, stage III, or stage IV relapsed or refractory
non-Hodgkin's lymphoma.
This is a phase I, dose-escalation study of motexafin gadolinium followed by a phase II
study. Patients are stratified according to extent of lymphomatous involvement (≤ 5% vs > 5
but ≤ 24% of cellular elements).
Cohorts of 3-6 patients in each stratum receive escalating doses of motexafin gadolinium
until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which
2 of 6 patients experience dose-limiting toxicity (DLT) OR the dose preceding that at which 2
of 3 or 3 of 6 patients experience DLT.
- Once the MTD is determined, additional patients are treated at that dose level as in
phase I.
Patients are followed weekly for 3 months and then monthly for 5 years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01448928 -
Zevalin Post-marketing Surveillance in Japan
|
||
| Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01758042 -
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
|
N/A | |
| Terminated |
NCT00185679 -
Haploid Allogeneic Transplant Using the CliniMACS System
|
Phase 2 | |
| Completed |
NCT01108341 -
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 2 | |
| Completed |
NCT00129090 -
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
|
Phase 3 | |
| Completed |
NCT01527838 -
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
|
Phase 1 | |
| Completed |
NCT00923910 -
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
|
Phase 1/Phase 2 | |
| Completed |
NCT00614042 -
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Completed |
NCT02071888 -
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
|
Phase 1 | |
| Recruiting |
NCT04696705 -
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients
|
Early Phase 1 | |
| Completed |
NCT01479387 -
Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan
|
N/A | |
| Completed |
NCT00889798 -
Tumor Registry of Lymphatic Neoplasia
|
||
| Terminated |
NCT05144347 -
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
|
Phase 1 |